Agilent Technologies Inc. stock (US00846U1016): shares firm after May earnings as life-science demand stabilizes

Agilent Technologies Inc. shares traded moderately higher on the New York Stock Exchange on Thursday, with the stock quoted around USD 137 in afternoon U.S. trading, according to Nasdaq data as of 06/04/2026. The U.S.-based life-science and diagnostics group, which is a member of major U.S. equity benchmarks, has been in focus since it released its latest quarterly results in May 2024.

In its fiscal second-quarter 2024 report published on 05/29/2024, Agilent Technologies said that revenue for the quarter ended 04/30/2024 came in at approximately USD 1.57 billion, roughly flat to slightly down versus the prior-year period, while adjusted earnings per share were reported at about USD 1.22, according to the company’s earnings press release on that date. The stock reaction since the publication has been relatively muted compared with more volatile moves in some other U.S. life-science tools names.

As of: 06/04/2026

By the editorial team - specialized in equity coverage.

Agilent Technologies Inc.: core business model

Agilent Technologies focuses on providing analytical instruments, consumables, and diagnostic solutions to laboratories in pharmaceuticals, chemicals, food testing, and clinical markets, generating most of its revenue from recurring consumables, services, and software tied to installed instruments.

Industry trends and competitive position

The life-science tools and diagnostics industry has been undergoing a period of normalization following the pandemic-driven surge in testing and research spending, with several major players signaling more subdued demand from biopharma and industrial customers through 2024. According to a sector overview by S&P Global published in 03/2024, the broader life-science tools segment is expected to grow at a mid-single-digit compound annual rate over the next several years, driven by continued investment in biopharmaceutical R&D, increased adoption of advanced analytical technologies, and ongoing demand for quality and safety testing in food and environmental markets.

Within this competitive landscape, Agilent Technologies operates alongside other large industry providers such as Thermo Fisher Scientific and Danaher, which also supply analytical instruments, reagents, and services at global scale. While each company has its own portfolio focus and end-market mix, all of them compete for laboratory budgets in pharmaceuticals, biotechnology, environmental testing, and academic research, where customers value reliability of instruments, breadth of applications, and service quality. Agilent’s emphasis on chromatography, mass spectrometry, and genomics workflows positions it to participate in multiple growth vectors, from biotherapeutics development to food safety testing.

Conclusion

Agilent Technologies Inc. shares on the NYSE are trading close to the USD 137 level following the company’s fiscal Q2 2024 report released on 05/29/2024, which showed quarterly revenue of about USD 1.57 billion and adjusted EPS near USD 1.22. The sector context of moderating yet still positive long-term growth expectations in life-science tools, as highlighted in a 03/2024 S&P Global study, provides an important backdrop for investors assessing demand patterns in Agilent’s core markets. How laboratory budgets in pharmaceuticals, food testing, and environmental analysis evolve over the coming quarters will be a key factor for the stock’s medium-term performance.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.